Dr. Tempero on New Therapies for Pancreatic Cancer

Margaret A. Tempero, MD
Published Online: Monday, Jan 13, 2014

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, gives an overview of new therapies for pancreatic cancer.

Pathways that are downstream of activated RAS, such as the MAPK and PI3K pathways, are potential targets for the treatment of pancreatic cancer.

Tempero says that stromal depleting agents are also in development. There is also an interest in optimizing vaccine strategies and changing the immune cell population in the microenvironment from a pro-tumor environment to an anti-tumor environment.

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, gives an overview of new therapies for pancreatic cancer.

Pathways that are downstream of activated RAS, such as the MAPK and PI3K pathways, are potential targets for the treatment of pancreatic cancer.

Tempero says that stromal depleting agents are also in development. There is also an interest in optimizing vaccine strategies and changing the immune cell population in the microenvironment from a pro-tumor environment to an anti-tumor environment.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Newer Options on the Horizon for Non-Small Cell Lung CancerJul 20, 20161.0
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 20, 20162.5